BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature

Despite the efficacy of osimertinib in the first-line treatment of advanced EGFR-mutated NSCLC, the development of resistance is nearly inevitable. BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR-mutated NSCLC receiving osimertinib and represent potential targetable alterat...

Full description

Saved in:
Bibliographic Details
Main Authors: Marianna Peroni, MD, Alessandro Leonetti, MD, PhD, Roberta Minari, MSc, PhD, Michela Verzè, MSc, Letizia Gnetti, MD, Lorena Bottarelli, MSc, PhD, Cinzia Azzoni, MSc, PhD, Marco Galaverni, MD, Nicola Simoni, MD, Gabriele Missale, MD, Elisabetta Biasini, MD, Marcello Tiseo, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR mutation
Osimertinib
Resistance
BRAF fusion
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000840
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the efficacy of osimertinib in the first-line treatment of advanced EGFR-mutated NSCLC, the development of resistance is nearly inevitable. BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR-mutated NSCLC receiving osimertinib and represent potential targetable alterations.In this case report, we discuss the rationale for EGFR-MEK co-inhibition in a patient with EGFR-mutated NSCLC treated with osimertinib that developed a CTNNA1-BRAF fusion at progression. In addition, we provide a brief overview of the current evidence of BRAF fusions as an acquired resistance mechanism to osimertinib and potential treatment strategies.
ISSN:2666-3643

Similar Items